Member Info for Krone

Utah - nonsense, this is very relevant in the context of the paper highlighted by Fadec.

Fadec - nice find!!

Stoney and Fadec....many thanks, all very promising for an exciting 2020!!!

Are we really the only Tyk2 molecules available for licensing? How do we know that?

https://twitter.com/RobinDavison2/status/1207704076441534464

https://twitter.com/HybridanLLP/status/1207322563136888833

RMM - thanks very much indeed for your and all other comments from the attendees yesterday. It was good to met Thoth, CFP, Colin and Elgouna. Sorry I didn't get to introduce myself to you and others.
I concur with the comments posted. This was my third AGM and I would say that the level of engagement was substantially greater than previous meetings. The responses to questions were as open and honest as they could be. There is clearly a very significant degree of frustration around the Sierra situation and I suspect NG is not held in particularly high regard by the Sareum team. I suspect that Stephen Parker was very direct when meeting with NG.
It was reassuring that the team had met with CRT on Monday and have clearly reiterated Sareum's position.
I concur with others re 1801 and SRI - whilst the report on findings has been completed we are just waiting on the DoD to give the nod for publication. The key message is that the data can be discussed with potential suitors under NDA and the clear sense I got was that discussions are taking place.
Overall I came away frustrated with the ongoing delays, which are almost entirely out of Sareum's control, reassured that everything that can be done is being done, and confident that the board are very tightly focused on getting the fat old lady up on stage. I certainly saw Stephen Parker in a different light in that he is clearly engaged and working hard in our best interests.

Citigate - is one of the most respected names in communications. We are experts in our fields, combining the expertise of bankers, fund managers, in-house investor relations, former journalists and creative communications professionals as well as sector and transaction specialists.......really?

Principle 10 – Communicate how the Company is governed and is performing by maintaining a dialogue with shareholders and other relevant stakeholders
The Company maintains a regular dialogue with stakeholders including shareholders to enable interested parties to make informed decisions about the Group and its performance.
The Board believes that transparency in its dealings offers a level of comfort to stakeholders and an understanding that their views will be listened to.
The Board already discloses the result of general meetings by way of announcement and discloses the proxy voting numbers to those attending the meetings. In future, in the event that a significant portion of voters have voted against a resolution, an explanation of what actions it intends to take to understand the reasons behind the vote will be included.

An interesting read but a crying shame that they don't appear to be doing anything!
https://citigatedewerogerson.com/expertise/investor-relations/

If Sar re-tweet then we will know that something is up...or not.

On further reflection, is this a pre AGM tease...
Janssen Biotech has signed a definitive agreement to buy rights to XBiotech’s investigational monoclonal antibody, bermekimab, for a cash consideration of $750m.

https://twitter.com/hybridanllp/status/1204798743427588098

RMM - thanks. Noted and agreed.

Thoth/RMM - So would you anticipate the dissenters will be voting against all resolutions or just resolutions 5 and 6!?

Sareum is considering a strategy that may see lupus or lupus nephritis (the kidney damage associated with later stages of the disease) become the lead indication(s) with SD-1801, in order to avoid the more competitive areas such as psoriasis. Lupus is being studied by BMS in a large Phase II study, which if successful, could see SDC0-1801 becoming a “fast follower” with a potentially better dual targeting mechanism.

Lupus has been historically extremely challenging indication for pharmaceutical development but, in recent months, the field has seen some unexpected positive results from AstraZeneca, Roche, Biogen and latterly Aurinia Pharmaceuticals. This may in turn prompt heightened interest from potential licensing partners.

It should be noted that there is no guarantee that Sierra will be successful in securing a licensing deal or other arrangement to allow development of SRA737 to continue. However, if there is an extended delay in finding a partner and no active development underway, CRT Pioneer Fund (the counterparty in the current licensing deal) may seek to recover rights under the diligence clauses. This would, however, be unlikely to be possible before 2021 (development continues for now and there needs to be a period in which there is no development for the clauses to kick in) and the fund would then have attempt to re-license it.
Sareum has a 27.5% economic interest in a licensing deal covering SRA737, which we assume would be maintained in the event of any transaction over the asset by Sierra. Marten & Co valued this interest in SRA737 at £20.3m last year, but the uncertainty over timelines and the indications that may be pursued means that this should be considered impaired, pending resolution of the situation.

An interesting but worrying read in respect of timescales.

https://quoteddata.com/research/sareum-holdings-tyking/

DEL - I’m a positive realist trying to remain optimistic one day at a time. Either way my shares are under my mattress and I ain’t letting any go under any circumstances.

A tired old cynic may say that the recent increase in SP is manipulation to take the heat out of the AGM....